| BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency C Sun, J Yin, Y Fang, J Chen, KJ Jeong, X Chen, CP Vellano, Z Ju, ... Cancer cell 33 (3), 401-416. e8, 2018 | 281 | 2018 |
| Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers C Sun, Y Fang, J Yin, J Chen, Z Ju, D Zhang, X Chen, CP Vellano, ... Science translational medicine 9 (392), eaal5148, 2017 | 230 | 2017 |
| Proteome instability is a therapeutic vulnerability in mismatch repair-deficient cancer DJ McGrail, J Garnett, J Yin, H Dai, DJH Shih, TNA Lam, Y Li, C Sun, Y Li, ... Cancer cell 37 (3), 371-386. e12, 2020 | 96 | 2020 |
| Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm DJ McGrail, CCJ Lin, J Garnett, Q Liu, W Mo, H Dai, Y Lu, Q Yu, Z Ju, J Yin, ... NPJ systems biology and applications 3 (1), 8, 2017 | 60 | 2017 |
| PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non‐small‐cell lung cancer Y Jiang, H Dai, Y Li, J Yin, S Guo, SY Lin, DJ McGrail International journal of cancer 144 (5), 1092-1103, 2019 | 47 | 2019 |
| WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer A Sand, M Piacsek, DL Donohoe, AT Duffin, GT Riddell, C Sun, M Tang, ... Cancer letters 472, 119-131, 2020 | 38 | 2020 |
| Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis J Wang, J Yin, Q Yang, F Ding, X Chen, B Li, X Tian Oncotarget 7 (47), 76693, 2016 | 38 | 2016 |
| The effect of Z-ligustilide on the mobility of human glioblastoma T98G cells J Yin, C Wang, A Mody, L Bao, SH Hung, SA Svoronos, Y Tseng PLoS One 8 (6), e66598, 2013 | 33 | 2013 |
| Characterization of MET exon 14 skipping alterations (in NSCLC) and identification of potential therapeutic targets using whole transcriptome sequencing SY Kim, J Yin, S Bohlman, P Walker, S Dacic, C Kim, H Khan, SV Liu, ... JTO clinical and research reports 3 (9), 100381, 2022 | 17 | 2022 |
| Non-canonical MLL1 activity regulates centromeric phase separation and genome stability L Sha, Z Yang, S An, W Yang, S Kim, H Oh, J Xu, J Yin, H Wang, HJ Lenz, ... Nature cell biology 25 (11), 1637-1649, 2023 | 15 | 2023 |
| Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med. 2017; 9 C Sun, Y Fang, J Yin, J Chen, Z Ju, D Zhang, X Chen, CP Vellano, ... PUBMED, 0 | 14 | |
| The glycosylation of immune checkpoints and their applications in oncology L Zheng, Q Yang, F Li, M Zhu, H Yang, T Tan, B Wu, M Liu, C Xu, J Yin, ... Pharmaceuticals 15 (12), 1451, 2022 | 11 | 2022 |
| Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases GK In, JR Ribeiro, J Yin, J Xiu, MA Bustos, F Ito, F Chow, G Zada, ... NPJ precision oncology 7 (1), 120, 2023 | 9 | 2023 |
| Differential regulation of human monocytes and NK cells by antibody-opsonized tumors J Yin, AJ Albers, TS Smith, GT Riddell, JO Richards Cancer Immunology, Immunotherapy 67, 1239-1250, 2018 | 9 | 2018 |
| Team triathlon effects on physiological, psychological, and immunological measures in women breast cancer survivors JA Tjoe, LB Piacentine, PE Papanek, H Raff, J Richards, AL Harkins, J Yin, ... Supportive Care in Cancer 28, 6095-6104, 2020 | 8 | 2020 |
| Decomposition of cell activities revealing the role of the cell cycle in driving biofunctional heterogeneity T Lan, M Yu, W Chen, J Yin, HT Chang, S Tang, Y Zhao, S Svoronos, ... Scientific reports 11 (1), 23431, 2021 | 6 | 2021 |
| Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. NPJ Syst Biol … DJ McGrail, CC Lin, J Garnett, Q Liu, W Mo, H Dai, Y Lu, Q Yu, Z Ju, J Yin, ... DOI: https://doi. org/10.1038/s41540-017-0011-6, 8, 0 | 6 | |
| Genomic-glycosylation aberrations in tumor initiation, progression and management CKM Ip, J Yin, PKS Ng, SY Lin, GB Mills AIMS Medical Science 3 (4), 386-416, 2016 | 5 | 2016 |
| 藁本内酯稳定剂的研制及稳定性考察 汪程远， 尹君 中国药房 23 (35), 3294-3296, 2012 | 3 | 2012 |
| Genetic profiling of African American patients with prostatic adenocarcinoma metastatic to the lymph nodes: a pilot study S Bidot, J Yin, P Zhou, L Zhang, KK Deeb, G Smith, CE Hill, J Xiu, ... Archives of Pathology & Laboratory Medicine 148 (3), 310-317, 2024 | 2 | 2024 |